

Patient ID	LSC17
590	high
110500	nd
90191	nd
110770	high
110102	high
100348	low
90668	low
120860	low
100753	high
120706	high




FIG. 1A




FIG. 1B

3/70






FIG. 1C








FIG. 2A continued




FIG. 2B




FIG. 2C




FIG. 3

10/70




FIG. 4

11/70




FIG. 4 continued

12/70




FIG. 5

13/70




FIG. 5 continued




FIG. 6

15/70





FIG. 6 continued






FIG. 7A continued




FIG. 7B




FIG. 7B continued




FIG. 7C

D. AML cell number transplanted

Sample ID	% of CD45+	Total cells	AML cells/mouse
		x10 ⁶	x10 ⁶
590 Vehicle	81.7	36.03	5.89
590 Compound D	0.425	52.35	0.04
110102 Vehicle	47.2	36.03	3.40
110102 Compound D	0.127	65.86	0.02
110770 Vehicle	14.7	41.09	1.21
110770 Compound D	0.402	55.73	0.04

FIG. 7D

22/70




FIG. 7E

A. Representative Gating Strategy for Vehicle




FIG. 8A




FIG. 8A continued

B. Representative Gating Strategy for Compound D




FIG. 8B




FIG. 8B continued





FIG. 9A







FIG. 9B continued






FIG. 9C continued








FIG. 9D









37/70




FIG. 11




FIG. 11 continued




FIG. 12A




FIG. 12A continued




FIG. 12A continued

B: Compound D induced differentiation of AML blasts




FIG. 12B

100474 2ndry M5a LSC17lo




FIG. 12B continued






FIG. 12B continued









FIG. 12C continued







FIG. 12D continued






FIG. 12E continued

52/70





FIG. 13




FIG. 14A




FIG. 14B




FIG. 14C

A: De novo vs Secondary AML




FIG. 15A

B: Adverse vs Intermediate prognosis




FIG. 15B

C: Cytogenetically normal vs abnormal AML




FIG. 15C

D: FLT3-ITD positive vs negative in CN-AML

SUBSTITUTE SHEET (RULE 26)




FIG. 15D

60/70

- 120347
- 121020
- 130607
- 130926
- 0598
- 120287
- 130311
- 130826
- 140005
- 140171
- 141104
- 150238
- 150250




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17




FIG. 17 continued




FIG. 18A

A: GSPT1 expression followed in vivo Compound D treatment




FIG. 18A continued




FIG. 18B




FIG. 18B continued




FIG. 19